Pei Wen Yu

Title: Pei Wen Yu: Innovator in Apoptosis Proteins

Introduction

Pei Wen Yu is a notable inventor based in Cupertino, CA (US). He has made significant contributions to the field of biotechnology, particularly in the area of apoptosis proteins. With a total of 5 patents to his name, his work has implications for both diagnosis and treatment of diseases.

Latest Patents

Pei Wen Yu's latest patents focus on novel apoptosis polypeptides, including Apop1, Apop2, and Apop3 proteins. These inventions are directed towards modulating apoptosis and include nucleic acid molecules that encode these polypeptides. His patents also cover vectors and host cells that comprise these nucleic acid sequences, as well as chimeric polypeptide molecules that fuse the polypeptides with heterologous sequences. Additionally, he has developed antibodies that bind to these polypeptides and methods for producing them. His work further includes methods for identifying novel compositions that modulate the biological activity of Apop1, Apop2, and Apop3, which can be utilized in the diagnosis and treatment of various diseases.

Career Highlights

Throughout his career, Pei Wen Yu has worked with prominent companies in the pharmaceutical industry, including Rigel Pharmaceuticals, Incorporated and Rigel Pharmaceuticals, Inc. His experience in these organizations has allowed him to advance his research and contribute to significant innovations in the field.

Collaborations

Pei Wen Yu has collaborated with notable colleagues, including Ying Luo and James B Lorens. These partnerships have likely enriched his research and expanded the impact of his inventions.

Conclusion

Pei Wen Yu's contributions to the field of apoptosis proteins demonstrate his innovative spirit and commitment to advancing medical science. His patents and collaborations reflect a dedication to improving diagnosis and treatment options for diseases.